Stay updated with breaking news from Daniel Ollendorf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The pharmaceutical industry is coming under fire again for their pricing as they are launching new medicines at record prices this year.
When Biogen cut the price of its Alzheimer's drug in half, it exposed the arbitrary nature of drug pricing.
The drugmaker and insurer's outcomes-based agreement offers rebates for ALK-positive NSCLC patients who discontinue Alunbrig after three months.